Uses of il-23 agonists and antagonists; related reagents

Abstract

Provided are methods of treatment for tumors. In particular, methods are provided for modulating activity of a cytokine molecule and its receptor.

1 - 18 . (canceled)  
     
     
         19 . A method of inhibiting tumor growth comprising contacting a tumor cell with an effective amount of a binding composition comprising an antigen-binding site of an antibody that specifically binds to IL-23.  
     
     
         20 . The method of  claim 19 , wherein the binding composition comprises an antigen-binding site of an antibody that specifically binds to a polypeptide consisting of residues 1-168 of SEQ ID NO: 2.  
     
     
         21 . The method of  claim 20 , wherein the tumor cell expresses IL-23.  
     
     
         22 . The method of  claim 20 , wherein the binding composition comprises a monoclonal antibody or an antigen-binding fragment thereof.  
     
     
         23 . The method of  claim 22 , wherein the binding composition comprises a humanized antibody or an antigen-binding fragment thereof.  
     
     
         24 . The method of  claim 20 , wherein the binding composition comprises an Fab, Fv, or F(ab′) 2  antibody fragment.  
     
     
         25 . The method of  claim 24 , wherein the binding composition comprises an Fab antibody fragment.  
     
     
         26 . The method of  claim 20 , wherein the tumor cell is a colon cancer cell.  
     
     
         27 . The method of  claim 20 , wherein the tumor cell is an ovarian cancer cell.  
     
     
         28 . The method of  claim 20 , wherein the tumor cell is a breast cancer cell.  
     
     
         29 . The method of  claim 20 , wherein the tumor cell is a melanoma cell.  
     
     
         30 . A method of treating a subject suffering from a cancer or tumor comprising administering to the subject an effective amount of a binding composition comprising an antigen-binding site of an antibody that specifically binds to IL-23.  
     
     
         31 . The method of  claim 30 , wherein the binding composition comprises an antigen-binding site of an antibody that specifically binds to a polypeptide consisting of residues 1-168 of SEQ ID NO: 2.  
     
     
         32 . The method of  claim 31 , wherein the binding composition inhibits cachexia.  
     
     
         33 . The method of  claim 31 , wherein the binding composition inhibits angiogenesis.  
     
     
         34 . The method of  claim 31 , wherein the binding composition comprises a monoclonal antibody or an antigen-binding fragment thereof.  
     
     
         35 . The method of  claim 34 , wherein the binding composition comprises a humanized antibody or an antigen-binding fragment thereof.  
     
     
         36 . The method of  claim 31 , wherein the binding composition comprises an Fab, Fv, or F(ab′) 2  antibody fragment.  
     
     
         37 . The method of  claim 36 , wherein the binding composition comprises an Fab antibody fragment.  
     
     
         38 . The method of  claim 31 , wherein the cancer or tumor is colon cancer.  
     
     
         39 . The method of  claim 31 , wherein the cancer or tumor is ovarian cancer.  
     
     
         40 . The method of  claim 31 , wherein the cancer or tumor is breast cancer.  
     
     
         41 . The method of  claim 31 , wherein the cancer or tumor is melanoma.  
     
     
         42 . A method of inhibiting tumor growth comprising contacting a tumor cell with an effective amount of a binding composition comprising an antigen-binding site of an antibody that specifically binds to a polypeptide consisting of the sequence of SEQ ID NO: 2.  
     
     
         43 . A method of treating a subject suffering from a cancer or tumor comprising administering to the subject an effective amount of a binding composition comprising an antigen-binding site of an antibody that specifically binds to a polypeptide consisting of the sequence of SEQ ID NO: 2.